Fennec Pharmaceuticals Inc (FRX)

Toronto
Currency in CAD
9.02
-0.46(-4.85%)
Closed

FRX Income Statement

Advanced Income Statement
Period Ending:
2014
31/12
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa-0.17-1.5421.25
Total Revenues Growth
aa.aaaa.aaaa.aaaa.aaaa.aa----+1,284.5%
Cost Of Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa---0.091.26
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa-0.17-1.4519.99
Gross Profit Growth
aa.aaaa.aaaa.aaaa.aaaa.aa----+1,279.78%
Gross Profit Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-100%-94.4%94.08%
Other Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa13.0118.0617.2224.0432.76
Other Operating Expenses, Total Growth
R&D Expenses
Selling General & Admin Expenses
Other Operating Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa+24.98%+38.79%-4.61%+39.57%+36.3%
aa.aaaa.aaaa.aaaa.aaaa.aa5.615.114.983.530.06
aa.aaaa.aaaa.aaaa.aaaa.aa7.412.9512.2420.5132.71
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa-13.01-17.89-17.22-22.59-12.77
Operating Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-24.98%-37.48%+3.7%-31.16%+43.46%
EBIT Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa--10,520.59%--1,471.6%-60.09%
Net Interest Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa0.25-0.32-0.09-0.93-3.24
Net Interest Expenses Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-27.87%-229.08%+72.84%-959.09%-247.64%
Interest Expense, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-0.06-0.41-0.14-1.13-3.68
Interest And Investment Income
aa.aaaa.aaaa.aaaa.aaaa.aa0.320.090.050.20.44
Other Non Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-0.02--0.01-0.010.01
EBT, Excl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa-12.78-18.21-17.32-23.53-16.01
Gain (Loss) On Sale Of Assets
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Other Unusual Items, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-----
EBT, Incl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa-12.78-18.11-17.35-23.71-16.05
EBT, Incl. Unusual Items Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-29.2%-41.75%+4.21%-36.71%+32.34%
EBT, Incl. Unusual Items Margin
aa.aaaa.aaaa.aaaa.aaaa.aa--10,652.35%--1,544.89%-75.5%
Income Tax Expense
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Net Income to Company
aa.aaaa.aaaa.aaaa.aaaa.aa-12.78-18.11-17.35-23.71-16.05
Minority Interest
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa-12.78-18.11-17.35-23.71-16.05
Net Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-29.2%-41.75%+4.21%-36.71%+32.34%
Net Income Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa--10,652.35%--1,544.89%-75.5%
Preferred Dividend and Other Adjustments
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Net Income to Common Excl. Extra Items
aa.aaaa.aaaa.aaaa.aaaa.aa-12.78-18.11-17.35-23.71-16.05
Basic EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-0.64-0.76-0.67-0.9-0.6
Basic EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-23%-18.98%+12.69%-35.31%+33.1%
Diluted EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-0.64-0.76-0.67-0.9-0.6
Diluted EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-23%-18.98%+12.3%-34.71%+33.1%
Basic Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa19.923.726.0126.2826.57
Diluted Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa19.923.726.0126.2826.57
Dividend Per Share
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Dividend Per Share Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-----
EBITDA
aa.aaaa.aaaa.aaaa.aaaa.aa-----
EBITDA Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-----
EBITDA Margin %
aa.aaaa.aa